CH627446A5
(fr)
|
1978-01-17 |
1982-01-15 |
Debiopharm Sa |
Nouveaux derives de la benzamide.
|
GB8302483D0
(en)
|
1983-01-29 |
1983-03-02 |
Beecham Group Plc |
Compounds
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
CZ284687B6
(cs)
|
1986-04-30 |
1999-02-17 |
Dainippon Pharmaceutical Co., Ltd. |
Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
SG48759A1
(en)
|
1990-01-12 |
2002-07-23 |
Abgenix Inc |
Generation of xenogenic antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
DE69133476T2
(de)
|
1990-08-29 |
2006-01-05 |
GenPharm International, Inc., Palo Alto |
Transgene Mäuse fähig zur Produktion heterologer Antikörper
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
JP2529912B2
(ja)
|
1990-10-16 |
1996-09-04 |
帝国化学産業株式会社 |
ベンズアミド誘導体
|
US5395832A
(en)
|
1991-02-15 |
1995-03-07 |
Hokuriku Seiyaku Co., Ltd. |
Benzamide derivatives
|
TW219935B
(ja)
|
1991-12-25 |
1994-02-01 |
Mitsubishi Chemicals Co Ltd |
|
US5236931A
(en)
|
1992-03-26 |
1993-08-17 |
A. H. Robins Company, Incorporated |
2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol
|
US5610052A
(en)
|
1992-08-26 |
1997-03-11 |
Ribozyme Pharmaceuticals Inc. |
Enzymatic RNA with activity to ras
|
EP0757985A4
(en)
|
1994-04-28 |
1997-09-03 |
Yamanouchi Pharma Co Ltd |
N- (3-PYRROLIDINYL) BENZAMIDE DERIVATIVE
|
EP1978033A3
(en)
|
1995-04-27 |
2008-12-24 |
Amgen Fremont Inc. |
Human antibodies derived from immunized xenomice
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
GB9525620D0
(en)
|
1995-12-15 |
1996-02-14 |
Glaxo Group Ltd |
Chemical compounds
|
EP0827742A1
(en)
|
1996-09-04 |
1998-03-11 |
Vrije Universiteit Brussel |
Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
|
GB9821483D0
(en)
|
1998-10-03 |
1998-11-25 |
Glaxo Group Ltd |
Chemical compounds
|
US6174905B1
(en)
|
1996-09-30 |
2001-01-16 |
Mitsui Chemicals, Inc. |
Cell differentiation inducer
|
DK0942968T3
(da)
|
1996-12-03 |
2008-06-23 |
Amgen Fremont Inc |
Fuldt humane antistoffer, der binder EGFR
|
GB9625145D0
(en)
|
1996-12-03 |
1997-01-22 |
Smithkline Beecham Plc |
Novel compounds
|
US6444849B1
(en)
|
1997-06-25 |
2002-09-03 |
Mitsubishi Chemical Corporation |
Amide derivatives
|
AU760562B2
(en)
|
1997-12-05 |
2003-05-15 |
Scripps Research Institute, The |
Humanization of murine antibody
|
US6140351A
(en)
|
1997-12-19 |
2000-10-31 |
Berlex Laboratories, Inc. |
Ortho-anthranilamide derivatives as anti-coagulants
|
US6673827B1
(en)
|
1999-06-29 |
2004-01-06 |
The Uab Research Foundation |
Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
|
SK286247B6
(sk)
|
1998-05-15 |
2008-06-06 |
Astrazeneca Ab |
Benzamidové deriváty, spôsob ich prípravy, farmaceutické prostriedky, ktoré ich obsahujú a ich použitie pri príprave liečiva na liečbu chorobných stavov sprostredkovaných cytokínmi
|
DE69919212T2
(de)
|
1998-12-23 |
2005-07-28 |
Eli Lilly And Co., Indianapolis |
Aromatische amiden
|
JP2000256194A
(ja)
|
1999-01-06 |
2000-09-19 |
Mitsui Chemicals Inc |
核内レセプタ作動薬およびその効果増強剤
|
EP1159264A2
(en)
|
1999-02-11 |
2001-12-05 |
Cor Therapeutics, Inc. |
INHIBITORS OF FACTOR Xa
|
TR200102568T2
(tr)
|
1999-03-17 |
2002-05-21 |
Astrazeneca Ab |
Amid türevleri.
|
JP2001081031A
(ja)
|
1999-08-30 |
2001-03-27 |
Schering Ag |
溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
|
JP4360660B2
(ja)
|
1999-11-09 |
2009-11-11 |
三井化学株式会社 |
モノアシルフェニレンジアミン誘導体の精製法
|
JP2003516150A
(ja)
|
1999-12-08 |
2003-05-13 |
ジェンセット |
潜在性分泌タンパク質をコードする全長ヒトcDNA
|
TWI284639B
(en)
|
2000-01-24 |
2007-08-01 |
Shionogi & Co |
A compound having thrombopoietin receptor agonistic effect
|
US7005439B2
(en)
|
2000-06-20 |
2006-02-28 |
Astrazeneca Ab |
Compounds
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
US6897220B2
(en)
|
2001-09-14 |
2005-05-24 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
US6706686B2
(en)
|
2001-09-27 |
2004-03-16 |
The Regents Of The University Of Colorado |
Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
|
TW200304374A
(en)
|
2001-11-30 |
2003-10-01 |
Smithkline Beecham Plc |
Novel compounds
|
US7993626B2
(en)
|
2007-01-11 |
2011-08-09 |
Immunomedics, Inc. |
Methods and compositions for F-18 labeling of proteins, peptides and other molecules
|
US20050215601A1
(en)
|
2002-09-25 |
2005-09-29 |
Santen Pharmaceutical Co., Ltd. |
Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
|
US8163896B1
(en)
|
2002-11-14 |
2012-04-24 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
US7217807B2
(en)
|
2002-11-26 |
2007-05-15 |
Rosetta Genomics Ltd |
Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
|
US20050054647A1
(en)
*
|
2002-12-27 |
2005-03-10 |
Detlev Schuppan |
New pharmaceutical combination
|
US7244751B2
(en)
|
2003-02-14 |
2007-07-17 |
Shenzhen Chipscreen Biosciences Ltd. |
Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
PE20050206A1
(es)
|
2003-05-26 |
2005-03-26 |
Schering Ag |
Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
|
TWI287010B
(en)
|
2003-06-12 |
2007-09-21 |
Euro Celtique Sa |
Therapeutic agents useful for treating pain
|
US9005613B2
(en)
|
2003-06-16 |
2015-04-14 |
Immunomedics, Inc. |
Anti-mucin antibodies for early detection and treatment of pancreatic cancer
|
CN1284772C
(zh)
|
2003-07-04 |
2006-11-15 |
深圳微芯生物科技有限责任公司 |
具有分化和抗增殖活性的苯甲酰胺类组蛋白去乙酰化酶抑制剂及其药用制剂
|
WO2005046516A2
(en)
|
2003-11-10 |
2005-05-26 |
Angiotech International Ag |
Medical implants and anti-scarring agents
|
US20130189364A1
(en)
|
2004-07-09 |
2013-07-25 |
Robert Sabin |
Compositions and methods of potentiating adjuvant pharmaceuticals targeting latent viral infections
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
JP5265204B2
(ja)
|
2005-03-04 |
2013-08-14 |
ライフスキャン・インコーポレイテッド |
成人膵臓由来間質細胞
|
US20090280153A1
(en)
|
2005-05-10 |
2009-11-12 |
Angiotech International Ag |
electrical devices, anti-scarring agents, and therapeutic compositions
|
WO2006135479A2
(en)
|
2005-05-10 |
2006-12-21 |
Angiotech International Ag |
Anti-scarring agents, therapeutic compositions, and use thereof
|
WO2006121521A2
(en)
|
2005-05-10 |
2006-11-16 |
Angiotech International Ag |
Soft tissue implants, anti-scarring agents, and therapeutic compositions
|
WO2006121522A2
(en)
|
2005-05-10 |
2006-11-16 |
Angiotech International Ag |
Implantable sensors and pumps, anti-scarring agents, and therapeutic compositions
|
US20090247734A1
(en)
|
2005-12-14 |
2009-10-01 |
Hendrickson Wayne A |
Chemically Derivatized CD4 and Uses Thereof
|
CA2639070A1
(en)
|
2006-04-13 |
2007-11-01 |
Oncomethylime Sciences S.A. |
Novel tumour suppressor
|
US20070292351A1
(en)
|
2006-05-26 |
2007-12-20 |
Methylgene, Inc. |
Assay for efficacy of histone deacetylase inhibitors
|
ZA200902382B
(en)
|
2006-10-19 |
2010-08-25 |
Signal Pharm Llc |
Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
|
EP2514762B1
(en)
|
2007-07-13 |
2015-04-08 |
The Johns Hopkins University |
B7-DC variants
|
WO2009023193A1
(en)
|
2007-08-15 |
2009-02-19 |
Cytokinetics, Incorporated |
Certain chemical entities, compositions, and methods
|
TW200924777A
(en)
|
2007-09-14 |
2009-06-16 |
Methylgene Inc |
Combination therapy
|
GB0802009D0
(en)
|
2008-02-04 |
2008-03-12 |
Chroma Therapeutics Ltd |
Biomarkers of aminopeptidase inhibition
|
JP2009209090A
(ja)
|
2008-03-04 |
2009-09-17 |
Mitsui Chemicals Inc |
殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法
|
WO2009147781A1
(ja)
|
2008-06-02 |
2009-12-10 |
国立大学法人東京大学 |
抗がん剤
|
AU2009288289B2
(en)
|
2008-08-25 |
2012-11-08 |
Amplimmune, Inc. |
PD-1 antagonists and methods of use thereof
|
TWI453207B
(zh)
|
2008-09-08 |
2014-09-21 |
Signal Pharm Llc |
胺基三唑并吡啶,其組合物及使用其之治療方法
|
US20160041153A1
(en)
|
2008-11-12 |
2016-02-11 |
Kirk Brown |
Biomarker compositions and markers
|
CN101756957B
(zh)
|
2008-12-26 |
2012-11-14 |
鼎泓国际投资(香港)有限公司 |
含有青蒿素及青蒿素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
|
CN101757626B
(zh)
|
2008-12-26 |
2012-12-12 |
鼎泓国际投资(香港)有限公司 |
含有胰岛素样生长因子-i受体抑制剂和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
|
CN101837129B
(zh)
|
2009-03-19 |
2012-12-12 |
鼎泓国际投资(香港)有限公司 |
含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用
|
CN101836989B
(zh)
|
2009-03-19 |
2013-02-13 |
鼎泓国际投资(香港)有限公司 |
含有粉防己碱及粉防己碱类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
|
EP2494077A4
(en)
|
2009-10-27 |
2013-08-21 |
Caris Mpi Inc |
MOLECULAR PROFILING FOR PERSONALIZED MEDICINE
|
EP2501237A1
(en)
|
2009-11-06 |
2012-09-26 |
Infinity Pharmaceuticals, Inc. |
Oral formulations of a hedgehog pathway inhibitor
|
CN102713606A
(zh)
|
2009-11-13 |
2012-10-03 |
无限制药股份有限公司 |
用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法
|
JP2013511549A
(ja)
|
2009-11-20 |
2013-04-04 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
ヘッジホッグ関連癌の治療のための方法及び組成物
|
RU2567753C2
(ru)
|
2010-02-11 |
2015-11-10 |
Селджин Корпорейшн |
Производные арилметокси изоиндолина и композиции, включающие их, и способы их применения
|
EP3153521B1
(en)
|
2010-03-26 |
2019-09-04 |
Trustees of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
WO2011127219A1
(en)
|
2010-04-06 |
2011-10-13 |
Caris Life Sciences Luxembourg Holdings |
Circulating biomarkers for disease
|
JO2998B1
(ar)
|
2010-06-04 |
2016-09-05 |
Amgen Inc |
مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
|
WO2011155898A1
(en)
|
2010-06-11 |
2011-12-15 |
Wadell Goeran |
New antiviral compounds
|
WO2012006589A2
(en)
|
2010-07-08 |
2012-01-12 |
Infinity Pharmaceuticals, Inc. |
Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
|
US20120010229A1
(en)
|
2010-07-08 |
2012-01-12 |
Macdougall John R |
Therapeutic regimens for hedgehog-associated cancers
|
EP2606353A4
(en)
|
2010-08-18 |
2014-10-15 |
Caris Life Sciences Luxembourg Holdings |
CIRCULATING BIOMARKERS FOR DISEASE
|
CN102441167B
(zh)
|
2010-10-12 |
2014-05-07 |
鼎泓国际投资(香港)有限公司 |
含有芹菜素及芹菜素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
|
US9808434B2
(en)
|
2011-01-27 |
2017-11-07 |
City Of Hope |
Compound for treating cancer and diabetes
|
WO2012115885A1
(en)
|
2011-02-22 |
2012-08-30 |
Caris Life Sciences Luxembourg Holdings, S.A.R.L. |
Circulating biomarkers
|
US20140349938A1
(en)
|
2011-06-03 |
2014-11-27 |
President And Fellows Of Harvard College |
Methods of diagnosing and treating amyotrophic lateral sclerosis
|
EP2718721A4
(en)
|
2011-06-07 |
2014-10-01 |
Caris Life Sciences Luxembourg Holdings S A R L |
CIRCULATING BIOMARKERS FOR CANCER
|
AU2012271516A1
(en)
|
2011-06-16 |
2014-01-23 |
Caris Life Sciences Switzerland Holdings Gmbh |
Biomarker compositions and methods
|
WO2013028907A1
(en)
|
2011-08-23 |
2013-02-28 |
Infinity Pharmaceuticals, Inc. |
Biomarkers predictive of therapeutic responsiveness to hsp90 inhibitors and uses thereof
|
WO2013039956A2
(en)
|
2011-09-14 |
2013-03-21 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for treating mood disorders
|
EA201490644A1
(ru)
|
2011-09-30 |
2014-09-30 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Терапевтические пептиды
|
US9365496B2
(en)
|
2011-11-30 |
2016-06-14 |
Ludwig Institute For Cancer Research |
iNKT cell modulators and methods of using the same
|
BR112014018481A2
(pt)
|
2012-02-01 |
2017-07-04 |
Compugen Ltd |
anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
|
WO2013124867A1
(en)
|
2012-02-21 |
2013-08-29 |
Amrita Vishwa Vidyapeetham University |
Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
|
CA2865335A1
(en)
|
2012-03-09 |
2013-09-12 |
Caris Life Sciences Luxembourg Holdings, S.A.R.L. |
Biomarker compositions and methods
|
CN104619718A
(zh)
|
2012-06-06 |
2015-05-13 |
比奥诺尔免疫有限公司 |
源自病毒蛋白的肽用作免疫原和配药成分
|
CN104717974A
(zh)
|
2012-06-06 |
2015-06-17 |
比奥诺尔免疫有限公司 |
疫苗
|
KR20150023811A
(ko)
|
2012-06-21 |
2015-03-05 |
컴퓨젠 엘티디. |
암의 치료를 위한 lsr 항체 및 그의 용도
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
HUE046292T2
(hu)
|
2012-08-13 |
2020-02-28 |
Univ Rockefeller |
Melanóma kezelése és diagnosztizálása
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
US9315567B2
(en)
|
2012-08-14 |
2016-04-19 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
CN104884065B
(zh)
|
2012-09-21 |
2019-01-01 |
强烈治疗剂公司 |
治疗癌症的方法
|
CN104903450A
(zh)
|
2012-11-05 |
2015-09-09 |
普隆奈治疗公司 |
寡核苷酸癌症疗法的给药和施用
|
AR093512A1
(es)
|
2012-11-16 |
2015-06-10 |
Merck Patent Gmbh |
Derivados heterociclicos como moduladores de la actividad de cinasas
|
US20150301058A1
(en)
|
2012-11-26 |
2015-10-22 |
Caris Science, Inc. |
Biomarker compositions and methods
|
CN103833626B
(zh)
|
2012-11-27 |
2015-11-25 |
深圳微芯生物科技有限责任公司 |
西达本胺的晶型及其制备方法与应用
|
CA2887539C
(en)
|
2012-11-29 |
2021-10-26 |
Merck Patent Gmbh |
Azaquinazoline carboxamide derivatives
|
CN107753954A
(zh)
|
2012-12-13 |
2018-03-06 |
免疫医疗公司 |
功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
|
ES2819573T3
(es)
|
2012-12-13 |
2021-04-16 |
Immunomedics Inc |
Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
CN105209068A
(zh)
|
2013-02-07 |
2015-12-30 |
免疫医疗公司 |
用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox)
|
CN104969664B
(zh)
|
2013-02-07 |
2018-05-22 |
飞利浦灯具控股公司 |
具有促成所选择的光场景的控制器的照明系统以及用于控制这样的系统的方法
|
CN104056270B
(zh)
|
2013-02-21 |
2018-11-09 |
中国人民解放军军事医学科学院野战输血研究所 |
用于制备多器官损伤救治药物的组蛋白去乙酰化酶抑制剂
|
CA2903903C
(en)
|
2013-03-05 |
2021-05-04 |
Merck Patent Gmbh |
Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer
|
WO2014135245A1
(en)
|
2013-03-05 |
2014-09-12 |
Merck Patent Gmbh |
9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
|
LT2970473T
(lt)
|
2013-03-14 |
2017-10-25 |
Bristol-Myers Squibb Company |
Dr5 agonisto ir anti-pd-1 antagonisto derinys ir naudojimo būdai
|
CA2899969A1
(en)
|
2013-03-14 |
2014-09-25 |
Seragon Pharmaceuticals, Inc. |
Polycyclic estrogen receptor modulators and uses thereof
|
EP2970965A2
(en)
|
2013-03-15 |
2016-01-20 |
Pronai Therapeutics, Inc. |
Dnai for the modulation of genes
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
US10745483B2
(en)
|
2013-03-15 |
2020-08-18 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
CN104069106A
(zh)
|
2013-03-27 |
2014-10-01 |
南通瑞思医药技术有限公司 |
苯甲酰胺类化合物在制备激活潜伏艾滋病病毒药物中的应用
|
SG11201508092YA
(en)
|
2013-04-18 |
2015-10-29 |
Immune Design Corp |
Gla monotherapy for use in cancer treatment
|
EP3003355A1
(en)
|
2013-05-24 |
2016-04-13 |
Cooper Human Systems LLC |
Methods and compositions for treatment of hiv infection
|
WO2014193999A2
(en)
|
2013-05-28 |
2014-12-04 |
Caris Science, Inc. |
Biomarker methods and compositions
|
CA2915534A1
(en)
|
2013-06-19 |
2014-12-24 |
Seragon Pharmaceuticals, Inc. |
Azetidine estrogen receptor modulators and uses thereof
|
EP3010501B1
(en)
|
2013-06-19 |
2021-11-03 |
Seragon Pharmaceuticals, Inc. |
Estrogen receptor modulator and uses thereof
|
CN105492439B
(zh)
|
2013-06-21 |
2019-11-22 |
齐尼思表观遗传学有限公司 |
作为溴结构域抑制剂的取代的双环化合物
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
WO2015013579A1
(en)
|
2013-07-26 |
2015-01-29 |
Update Pharma Inc. |
Compositions to improve the therapeutic benefit of bisantrene
|
JP6417415B2
(ja)
|
2013-07-29 |
2018-11-07 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
1,3−二置換シクロペンタン誘導体
|
US9751832B2
(en)
|
2013-07-30 |
2017-09-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Selective histone deactylase 6 inhibitors
|
WO2015015318A2
(en)
|
2013-07-31 |
2015-02-05 |
Zenith Epigenetics Corp. |
Novel quinazolinones as bromodomain inhibitors
|
EP3027598B1
(en)
|
2013-07-31 |
2017-04-12 |
Merck Patent GmbH |
Oxoquinazolinyl-butanamide derivatives
|
WO2015019284A2
(en)
|
2013-08-05 |
2015-02-12 |
Cambridge Enterprise Limited |
Inhibition of cxcr4 signaling in cancer immunotherapy
|
AU2014304953B2
(en)
|
2013-08-07 |
2018-02-22 |
Merck Patent Gmbh |
Piperidine urea derivatives
|
US20160201063A1
(en)
|
2013-08-16 |
2016-07-14 |
Rana Therapeutics, Inc. |
Epigenetic regulators of frataxin
|
CN103432077A
(zh)
|
2013-08-21 |
2013-12-11 |
北京淦航医药科技有限公司 |
西达苯胺固体分散制剂
|
US10966998B2
(en)
|
2013-09-05 |
2021-04-06 |
The Johns Hopkins University |
Cancer therapy via a combination of epigenetic modulation and immune modulation
|
WO2015037005A1
(en)
|
2013-09-11 |
2015-03-19 |
Compugen Ltd. |
Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
|
WO2015037000A1
(en)
|
2013-09-11 |
2015-03-19 |
Compugen Ltd |
Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
|
WO2015048547A2
(en)
|
2013-09-26 |
2015-04-02 |
Rigel Pharmaceuticals, Inc. |
Methods for using and biomarkers for ampk-activating compounds
|
US20150094518A1
(en)
|
2013-09-27 |
2015-04-02 |
The Regents Of The University Of California |
Modular polymer platform for the treatment of cancer
|
EP3060654B1
(en)
|
2013-10-21 |
2023-03-15 |
Hemoshear, LLC |
In vitro model for a tumor microenvironment
|
PL3060550T3
(pl)
|
2013-10-21 |
2019-10-31 |
Merck Patent Gmbh |
Związki heteroarylowe jako inhibitory btk i ich zastosowanie
|
US20170080093A1
(en)
|
2013-10-22 |
2017-03-23 |
Tyme, Inc. |
Tyrosine Derivatives And Compositions Comprising Them
|
TR201810944T4
(tr)
|
2013-10-25 |
2018-08-27 |
Novartis Ag |
Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri.
|
US9457019B2
(en)
|
2013-11-07 |
2016-10-04 |
Deciphera Pharmaceuticals, Llc |
Methods for inhibiting tie-2 kinase useful in the treatment of cancer
|
KR20210063475A
(ko)
|
2013-11-07 |
2021-06-01 |
데시페라 파마슈티칼스, 엘엘씨. |
암치료에 유용한 tie2 키나아제의 억제 방법
|
EP3068443B1
(en)
|
2013-11-12 |
2019-04-10 |
Centre for Probe Development and Commercialization |
Residualizing linkers and uses thereof
|
WO2015073644A1
(en)
|
2013-11-13 |
2015-05-21 |
Novartis Ag |
Mtor inhibitors for enhancing the immune response
|
EP3071205B1
(en)
|
2013-11-18 |
2020-02-05 |
Forma Therapeutics, Inc. |
Benzopiperazine compositions as bet bromodomain inhibitors
|
JP6553632B2
(ja)
|
2013-11-18 |
2019-07-31 |
フォーマ セラピューティクス,インコーポレイテッド |
Betブロモドメイン阻害剤としてのテトラヒドロキノリン組成物
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
MX371187B
(es)
|
2013-12-06 |
2020-01-22 |
Dana Farber Cancer Inst Inc |
Péptidos terapéuticos.
|
WO2015086738A2
(en)
|
2013-12-11 |
2015-06-18 |
Bionor Immuno As |
Hiv vaccine
|
WO2015089380A2
(en)
|
2013-12-12 |
2015-06-18 |
Celcuity Llc |
Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
|
US20160263092A1
(en)
|
2013-12-19 |
2016-09-15 |
Twi Biotechnology, Inc. |
Therapeutic uses of berberine formulations
|
EP3686200A3
(en)
|
2013-12-20 |
2020-09-09 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
CN106456724A
(zh)
|
2013-12-20 |
2017-02-22 |
博德研究所 |
使用新抗原疫苗的联合疗法
|
NO3087076T3
(ja)
|
2013-12-23 |
2018-02-24 |
|
|
ES2815098T3
(es)
|
2013-12-23 |
2021-03-29 |
Bayer Pharma AG |
Conjugados de ligadores (ADCs) con inhibidores de KSP
|
AU2015204572B2
(en)
|
2014-01-10 |
2020-07-30 |
Inspirna, Inc. |
LXR agonists and uses thereof
|
CN104771363A
(zh)
|
2014-01-14 |
2015-07-15 |
深圳微芯生物科技有限责任公司 |
一种西达本胺固体分散体及其制备方法与应用
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
WO2015110659A1
(en)
|
2014-01-27 |
2015-07-30 |
Bionor Immuno As |
Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
|
WO2015110665A1
(en)
|
2014-01-27 |
2015-07-30 |
Bionor Immuno As |
Dosage regimen for hiv vaccine
|
US10143737B2
(en)
|
2014-01-27 |
2018-12-04 |
Bionor Pharma Asa |
Method for the vaccination against HIV
|
US9631013B2
(en)
|
2014-01-28 |
2017-04-25 |
Fibrogen, Inc. |
Therapeutic method for pancreatic cancer
|
WO2015113927A1
(en)
|
2014-01-29 |
2015-08-06 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted isothiazoles
|
JP2017512184A
(ja)
|
2014-01-29 |
2017-05-18 |
バイエル ファーマ アクチエンゲゼルシャフト |
アミノ置換されたイソチアゾール類
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
WO2015120382A1
(en)
|
2014-02-07 |
2015-08-13 |
The Johns Hopkins University |
Predicting response to epigenetic drug therapy
|
CA2936886A1
(en)
|
2014-02-27 |
2015-08-03 |
Merck Patent Gmbh |
Heterocyclic compounds as nav channel inhibitors and uses thereof
|
US9828399B2
(en)
|
2014-02-28 |
2017-11-28 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
TC-PTP inhibitors as APC activators for immunotherapy
|
WO2015135035A2
(en)
|
2014-03-11 |
2015-09-17 |
The Council Of The Queensland Institute Of Medical Research |
Determining cancer agressiveness, prognosis and responsiveness to treatment
|
AU2015228859A1
(en)
|
2014-03-13 |
2016-07-07 |
F. Hoffmann-La Roche Ag |
Therapeutic combinations with estrogen receptor modulators
|
RU2016137150A
(ru)
|
2014-03-13 |
2018-04-18 |
Ф. Хоффманн-Ля Рош Аг |
Способы и композиции для модулирования мутантов эстрогеновых рецепторов
|
HUE048531T2
(hu)
|
2014-03-14 |
2020-07-28 |
Novartis Ag |
Antitest molekulák a LAG-3-hoz és ezek felhasználása
|
SG10201808053XA
(en)
|
2014-03-19 |
2018-10-30 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
UY36060A
(es)
|
2014-04-02 |
2015-10-30 |
Bayer Pharma AG |
Compuestos de azol sustituidos con amida
|
CN104974079A
(zh)
|
2014-04-02 |
2015-10-14 |
C&C生物医药有限公司 |
苯胺相关化合物的酰胺衍生物及其组合物
|
EP3129472A4
(en)
|
2014-04-03 |
2017-11-01 |
University of Maryland, Baltimore |
Microtentacle imaging in patient tumor samples
|
CN103880736B
(zh)
|
2014-04-04 |
2017-05-17 |
深圳微芯生物科技有限责任公司 |
一种e构型苯甲酰胺类化合物及其药用制剂与应用
|
US9987258B2
(en)
*
|
2014-04-06 |
2018-06-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Histone deacetylase as a modulator of PDL1 expression and activity
|
CN106536507B
(zh)
|
2014-04-08 |
2020-04-07 |
里格尔药品股份有限公司 |
作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法
|
NO2776305T3
(ja)
|
2014-04-23 |
2018-01-27 |
|
|
JP2015209376A
(ja)
|
2014-04-24 |
2015-11-24 |
国立大学法人北海道大学 |
腫瘍特異的免疫増強剤
|
ES2885451T3
(es)
|
2014-04-30 |
2021-12-13 |
Inspirna Inc |
Inhibidores del transporte de creatina y usos de los mismos
|
WO2015168614A2
(en)
|
2014-05-01 |
2015-11-05 |
Board Of Regents Of The University Of Nebraska |
Polymer compositions of histone deacetylase inhibitors and methods of use thereof
|
WO2015172747A1
(en)
|
2014-05-16 |
2015-11-19 |
Zhaoyin Wang |
Spirocyclic molecules as mth1 inhibitors
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
WO2015184405A1
(en)
|
2014-05-30 |
2015-12-03 |
Medivation Technologies, Inc. |
Aromatic compounds, compositions and uses thereof
|
WO2015191568A2
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
|
TW202134236A
(zh)
|
2014-06-12 |
2021-09-16 |
美商西爾拉癌症醫學公司 |
N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
|
CN106660994A
(zh)
|
2014-06-13 |
2017-05-10 |
吉利德科学公司 |
磷脂酰肌醇3‑激酶抑制剂
|
WO2015191752A1
(en)
|
2014-06-13 |
2015-12-17 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
NZ726055A
(en)
|
2014-06-13 |
2018-04-27 |
Gilead Sciences Inc |
Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
|
KR20170012560A
(ko)
|
2014-06-13 |
2017-02-02 |
길리애드 사이언시즈, 인코포레이티드 |
포스파티딜이노시톨 3-키나제 억제제
|
JP6346964B2
(ja)
|
2014-06-13 |
2018-06-20 |
ギリアード サイエンシーズ, インコーポレイテッド |
ホスファチジルイノシトール3−キナーゼ阻害剤
|
DK3154957T3
(da)
|
2014-06-16 |
2020-02-17 |
Fundacion Para La Investig Medica Aplicada |
Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser
|
AR100886A1
(es)
|
2014-06-17 |
2016-11-09 |
Bayer Pharma AG |
3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
|
TW201613936A
(en)
|
2014-06-20 |
2016-04-16 |
Gilead Sciences Inc |
Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
|
NO2717902T3
(ja)
|
2014-06-20 |
2018-06-23 |
|
|
NZ727185A
(en)
|
2014-06-24 |
2018-04-27 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors
|
EP3160493A4
(en)
|
2014-06-26 |
2018-04-11 |
Yale University |
Compositions and methods to regulate renalase in the treatment of diseases and disorders
|
JP2017523166A
(ja)
*
|
2014-07-11 |
2017-08-17 |
ビオノール イミュノ エーエスBionor Immuno As |
ヒト免疫不全ウイルスi(hiv)の病理学的影響を減少及び/若しくは遅延させるか又は後天性免疫不全症候群(aids)を発症するリスクを低減させる方法
|
JP6522732B2
(ja)
|
2014-07-11 |
2019-05-29 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hivを治療するためのトール様受容体の調節因子
|
EP3169326B1
(en)
|
2014-07-15 |
2021-03-31 |
The Johns Hopkins University |
Suppression of myeloid derived suppressor cells and immune checkpoint blockade
|
CN104083763A
(zh)
|
2014-07-16 |
2014-10-08 |
中国人民解放军军事医学科学院野战输血研究所 |
组蛋白去乙酰化酶抑制剂在制备潜伏病毒激活剂中的应用
|
CA2950238A1
(en)
|
2014-07-17 |
2016-01-21 |
Merck Patent Gmbh |
Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors
|
WO2016014890A1
(en)
|
2014-07-24 |
2016-01-28 |
Calithera Biosciences, Inc. |
Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
|
WO2016012477A1
(en)
|
2014-07-25 |
2016-01-28 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted isoxazoles
|
ES2811974T3
(es)
|
2014-07-29 |
2021-03-15 |
Novartis Ag |
Regímenes de aumento escalonado de la dosis del heterodímero de il-15 e il-15ralfa para tratar afecciones
|
TWI700283B
(zh)
|
2014-08-04 |
2020-08-01 |
德商拜耳製藥公司 |
2-(嗎啉-4-基)-1,7-萘啶
|
WO2016022955A1
(en)
|
2014-08-07 |
2016-02-11 |
Mayo Foundation For Medical Education And Research |
Compounds and methods for treating cancer
|
GB201414464D0
(en)
|
2014-08-14 |
2014-10-01 |
Technion Res & Dev Foundation |
Compositions and methods for therapeutics prescreening
|
TWI573794B
(zh)
|
2014-08-18 |
2017-03-11 |
小野藥品工業股份有限公司 |
TrK阻礙化合物之酸附加鹽
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
EP3597176A1
(en)
|
2014-08-19 |
2020-01-22 |
The Regents Of The University Of California |
Implants for localized drug delivery and methods of use thereof
|
EP3185903A1
(en)
|
2014-08-26 |
2017-07-05 |
Fundación para la Investigación Médica Aplicada |
Products for the treatment and prevention of neurological disorders coursing with a cognition deficit or impairment, and of neurodegenerative diseases
|
NZ729150A
(en)
|
2014-08-29 |
2018-02-23 |
Gilead Sciences Inc |
Antiretroviral agents
|
WO2016036759A1
(en)
|
2014-09-04 |
2016-03-10 |
Gilead Sciences, Inc. |
Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
|
US9993551B2
(en)
|
2014-09-13 |
2018-06-12 |
Novartis Ag |
Combination therapies of EGFR inhibitors
|
JP2017526730A
(ja)
|
2014-09-16 |
2017-09-14 |
ギリアード サイエンシーズ, インコーポレイテッド |
Toll様受容体モジュレーターの固体形態
|
JP6777638B2
(ja)
|
2014-09-19 |
2020-10-28 |
マッカイ メディカル ファンデーション ザ プレスビュテロス チャーチ イン タイワン マッカイ メモリアル ホスピタル |
ベンゾ複素環化合物および薬剤
|
US20170275270A1
(en)
|
2014-09-19 |
2017-09-28 |
Bayer Pharma Aktiengesellschaft |
Benzyl substituted indazoles
|
WO2016042080A1
(en)
|
2014-09-19 |
2016-03-24 |
Bayer Pharma Aktiengesellschaft |
Benzyl substituted indazoles as bub1 kinase inhibitors
|
EP3194381A1
(en)
|
2014-09-19 |
2017-07-26 |
Bayer Pharma Aktiengesellschaft |
Benzyl substituted indazoles as bub1 kinase inhibitors
|
PE20170697A1
(es)
|
2014-09-19 |
2017-06-24 |
Bayer Pharma AG |
Indazoles sustituidos con benzilo como inhibidores de bub1
|
WO2016046346A1
(en)
|
2014-09-24 |
2016-03-31 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Monolayer of pbmcs or bone-marrow cells and uses thereof
|
CN104530415B
(zh)
|
2014-10-01 |
2017-09-01 |
厦门赛诺邦格生物科技股份有限公司 |
一种异官能化y型聚乙二醇衍生物、制备方法及其生物相关物质
|
CN104725628B
(zh)
|
2014-10-01 |
2018-04-17 |
厦门赛诺邦格生物科技股份有限公司 |
一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
|
CN104530413B
(zh)
|
2014-10-01 |
2017-08-25 |
厦门赛诺邦格生物科技股份有限公司 |
一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
|
ES2774448T3
(es)
|
2014-10-03 |
2020-07-21 |
Novartis Ag |
Terapias de combinación
|
MX2017004200A
(es)
|
2014-10-06 |
2017-06-15 |
Merck Patent Gmbh |
Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
|
US9446148B2
(en)
|
2014-10-06 |
2016-09-20 |
Mayo Foundation For Medical Education And Research |
Carrier-antibody compositions and methods of making and using the same
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2016061087A1
(en)
|
2014-10-14 |
2016-04-21 |
The Usa, As Represented By The Secretary, Dept. Of Health & Human Services |
Peptide-based methods for treating pancreatic cancer
|
TN2017000129A1
(en)
|
2014-10-14 |
2018-10-19 |
Dana Farber Cancer Inst Inc |
Antibody molecules to pd-l1 and uses thereof
|
WO2016061495A1
(en)
|
2014-10-16 |
2016-04-21 |
Predictive Therapeutics Ltd. |
Atavarsitic systems and methods for biomarker discovery
|
US10889812B2
(en)
|
2014-10-24 |
2021-01-12 |
University Of Maryland, Baltimore |
Short non-coding protein regulatory RNAs (sprRNAs) and methods of use
|
US20180289689A1
(en)
|
2014-10-27 |
2018-10-11 |
Ruprecht-Karls-Universität Heidelberg |
Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
|
RU2695521C9
(ru)
|
2014-10-30 |
2019-08-19 |
Канпу Биофармасьютикалс, Лтд. |
Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение
|
BR112017008945A2
(pt)
|
2014-10-31 |
2018-01-16 |
Abbvie Biotherapeutics Inc |
Anticorpos anti-cs1 e conjugados fármaco- anticorpo
|
US20180298447A1
(en)
|
2014-11-07 |
2018-10-18 |
Rheinisch Friedrich-Wilhelms-Universität Bonn Institut Für Rekonstruktive Neurobiologie |
Methods for assessing the treatment response of cancer patients and for treating cancer patients by analysing cpg methylation
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CA2967188A1
(en)
|
2014-11-14 |
2016-05-19 |
Novartis Ag |
Antibody drug conjugates
|
JP6832861B2
(ja)
|
2014-11-17 |
2021-02-24 |
セレクター・バイオサイエンシズ・インコーポレイテッド |
癌標的化薬物ビヒクルとしてのリン脂質エーテル類似体
|
US10526341B2
(en)
|
2014-11-19 |
2020-01-07 |
Memorial Sloan-Kettering Cancer Center |
Thienopyrimidines and uses thereof
|
AU2015349899B9
(en)
|
2014-11-20 |
2020-06-25 |
Merck Patent Gmbh |
Heteroaryl compounds as IRAK inhibitors and uses thereof
|
US10710992B2
(en)
|
2014-12-01 |
2020-07-14 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
US20180148789A1
(en)
|
2014-12-01 |
2018-05-31 |
University Of Southern California |
Methods for treating and assessing tumor invasion and metastasis
|
WO2016087942A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Corp. |
Substituted pyridines as bromodomain inhibitors
|
WO2016087490A1
(en)
|
2014-12-03 |
2016-06-09 |
Bayer Pharma Aktiengesellschaft |
Combination of pi3k-inhibitors
|
WO2016087488A1
(en)
|
2014-12-03 |
2016-06-09 |
Bayer Pharma Aktiengesellschaft |
Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives
|
EP3227340B1
(en)
|
2014-12-04 |
2020-06-17 |
Mediterranea Theranostic S.R.L. |
Humanized anti-trop-2 monoclonal antibodies and uses thereof
|
WO2016094273A1
(en)
|
2014-12-08 |
2016-06-16 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
|
CA2969952A1
(en)
|
2014-12-09 |
2016-06-16 |
Adam James Davenport |
1,3-thiazol-2-yl substituted benzamides
|
WO2016094309A1
(en)
|
2014-12-10 |
2016-06-16 |
Myosotis |
Inhibition of tnf signaling in cancer immunotherapy
|
JP6782698B2
(ja)
|
2014-12-12 |
2020-11-11 |
セルキュイティー インコーポレイテッド |
がん患者を診断および処置するためのerbbシグナル伝達経路活性の測定方法
|
CA2970565A1
(en)
|
2014-12-15 |
2016-06-23 |
Bayer Pharma Aktiengesellschaft |
Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies
|
WO2016100619A2
(en)
|
2014-12-17 |
2016-06-23 |
Rgenix, Inc. |
Treatment and diagnosis of cancer
|
JP2017538727A
(ja)
|
2014-12-18 |
2017-12-28 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
癌の治療に有用な2,3−ジフェニルクロメンの誘導体
|
CA2970987A1
(en)
|
2014-12-18 |
2016-06-23 |
Bayer Pharma Aktiengesellschaft |
Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
|
WO2016097071A1
(en)
|
2014-12-18 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
Estrogen receptor modulators and uses thereof
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
AU2015367509B2
(en)
|
2014-12-18 |
2020-01-02 |
F. Hoffmann-La Roche Ag |
Tetrahydro-pyrido(3,4-b)indole estrogen receptor modulators and uses thereof
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
HUE044055T2
(hu)
|
2014-12-19 |
2019-09-30 |
Epigenomics Ag |
A CPG metiláció kimutatására és a rák diagnosztizálására szolgáló eljárások
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
WO2016102493A1
(en)
|
2014-12-22 |
2016-06-30 |
Bayer Pharma Aktiengesellschaft |
Imidazopyridine ezh2 inhibitors
|
EP3240784A2
(en)
|
2014-12-23 |
2017-11-08 |
BerGenBio ASA |
Inhibitors of akt kinase
|
TWI738321B
(zh)
|
2014-12-23 |
2021-09-01 |
美商基利科學股份有限公司 |
多環胺甲醯基吡啶酮化合物及其醫藥用途
|
CN107108636A
(zh)
|
2014-12-23 |
2017-08-29 |
拜耳医药股份公司 |
6‑羟基苯并呋喃基‑和6‑烷氧基苯并呋喃基‑取代的咪唑并哒嗪
|
DE102014226903A1
(de)
|
2014-12-23 |
2016-06-23 |
Olympus Winter & Ibe Gmbh |
HF-Hilfsstoff, medizinisches System und Verfahren zum selektiven Behandeln von Krebsgewebe
|
CA2972014C
(en)
|
2014-12-24 |
2019-09-24 |
Gilead Sciences, Inc. |
Fused pyrimidine compounds for the treatment of hiv
|
NZ733125A
(en)
|
2014-12-24 |
2018-06-29 |
Gilead Sciences Inc |
Isoquinoline compounds for the treatment of hiv
|
TW202237569A
(zh)
|
2014-12-24 |
2022-10-01 |
美商基利科學股份有限公司 |
喹唑啉化合物
|
WO2016112245A1
(en)
|
2015-01-08 |
2016-07-14 |
Hackensack University Medical Center |
Ex vivo methods for minimizing risks and maximizing benefits of allogeneic blood and marrow transplantation
|
EP3693022A3
(en)
|
2015-01-09 |
2020-09-16 |
Reiley Pharmaceuticals, Inc. |
Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
|
AU2016209046A1
(en)
|
2015-01-23 |
2017-07-20 |
Aclaris Therapeutics, Inc. |
Heterocyclic ITK inhibitors for treating inflammation and cancer
|
JP6655249B2
(ja)
|
2015-01-23 |
2020-02-26 |
国立大学法人 鹿児島大学 |
Hiv−1感染細胞殺傷剤及びその用途
|
EA032530B1
(ru)
|
2015-01-28 |
2019-06-28 |
Байер Фарма Акциенгезельшафт |
4h-пирроло[3,2-c]пиридин-4-оновые производные
|
SG10201803508WA
(en)
|
2015-01-30 |
2018-05-30 |
Oncoceutics Inc |
7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy
|
TW201639573A
(zh)
|
2015-02-03 |
2016-11-16 |
吉李德科學股份有限公司 |
有關治療癌症之合併治療
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
RU2730016C2
(ru)
|
2015-02-05 |
2020-08-14 |
Мерк Патент Гмбх |
Макроциклические соединения в качестве irak1/4 ингибиторов и их применение
|
MX2017009624A
(es)
|
2015-02-06 |
2017-11-20 |
Merck Patent Gmbh |
Macrociclos de piridazinona como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
|
MY193968A
(en)
|
2015-02-12 |
2022-11-03 |
Beyondspring Pharmaceuticals Inc |
Use of plinabulin in combination with immune checkpoint inhibitors
|
US10052346B2
(en)
|
2015-02-17 |
2018-08-21 |
Cantex Pharmaceuticals, Inc. |
Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
|
CN107427501B
(zh)
|
2015-02-20 |
2023-12-01 |
第一三共株式会社 |
通过联合使用治疗癌症的方法
|
EA037112B1
(ru)
|
2015-03-02 |
2021-02-08 |
Ригель Фармасьютикалс, Инк. |
Ингибиторы tgf-
|
RS56787B1
(sr)
|
2015-03-04 |
2018-04-30 |
Gilead Sciences Inc |
Toll-like receptor koji modulira jedinjenja 4,6-diamino-pirido[3,2-d]pirimidina
|
SG11201707239WA
(en)
|
2015-03-09 |
2017-10-30 |
Bayer Pharma AG |
Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
|
EP3268490B1
(en)
|
2015-03-09 |
2020-07-08 |
Bayer Pharma Aktiengesellschaft |
Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
|
EP3268044A2
(en)
|
2015-03-11 |
2018-01-17 |
The Broad Institute Inc. |
Prmt5 inhibitors for the treatment of cancer with reduced mtap activty
|
EP3988106A1
(en)
|
2015-03-13 |
2022-04-27 |
Ospedale San Raffaele S.r.l. |
Il-10-producing cd4+ t cells and uses thereof
|
US10195237B2
(en)
|
2015-03-16 |
2019-02-05 |
Imagilin Technology Llc |
Compositions and methods for treating inflammatory related diseases or conditions using Pediococcus acidilactici probiotics
|
WO2016149366A1
(en)
|
2015-03-16 |
2016-09-22 |
The Johns Hopkins University |
Methods and compositions for treating cancer
|
US10946050B2
(en)
|
2015-03-16 |
2021-03-16 |
Imagilin Technology Llc |
Compositions comprising probiotics and methods of use thereof
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
KR20170124604A
(ko)
|
2015-03-20 |
2017-11-10 |
신닥스 파마슈티컬스, 인크. |
암 치료를 위한 hdac 억제제 및 항pd-1 항체의 조합
|
WO2016153948A1
(en)
|
2015-03-20 |
2016-09-29 |
Deuterx, Llc |
Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders
|
WO2016153839A1
(en)
|
2015-03-20 |
2016-09-29 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and vorinostat for treating cancer
|
WO2016154082A2
(en)
|
2015-03-23 |
2016-09-29 |
Tang Yao |
Methods of primary tissue culture and drug screening using autologous serum and fluids
|
MX2017012131A
(es)
|
2015-03-25 |
2018-06-15 |
Univ Michigan Regents |
Composiciones y métodos para la administración de agentes de biomacromoléculas.
|
US10302629B2
(en)
|
2015-03-30 |
2019-05-28 |
University Of Maryland, Baltimore |
Compositions and methods for treating cancer by rational targeting of protein translation
|
CN107531727B
(zh)
|
2015-04-02 |
2019-11-29 |
吉利德科学公司 |
多环氨甲酰基吡啶酮化合物及其药物用途
|
TWI700298B
(zh)
|
2015-04-13 |
2020-08-01 |
美商輝瑞股份有限公司 |
靶向b細胞成熟抗原之嵌合型抗原受體類
|
WO2016166600A1
(en)
|
2015-04-15 |
2016-10-20 |
Trojantec Technologies Ltd |
Delivery of microrna using mesenchymal stem cell microparticles
|
US10774047B2
(en)
|
2015-04-17 |
2020-09-15 |
The Trustees Of The University Of Pennsylvania |
Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy
|
BR112017023228A2
(pt)
|
2015-04-29 |
2018-11-06 |
Radius Pharmaceuticals Inc |
métodos para tratamento de câncer
|
TW201701879A
(zh)
|
2015-04-30 |
2017-01-16 |
拜耳製藥公司 |
Irak4抑制劑組合
|
WO2016177833A1
(en)
|
2015-05-04 |
2016-11-10 |
Bionor Immuno As |
Dosage regimen for hiv vaccine
|
AU2016257302A1
(en)
|
2015-05-05 |
2017-11-16 |
Bayer Pharma Aktiengesellschaft |
Amido-substituted cyclohexane derivatives
|
US10314854B2
(en)
|
2015-05-15 |
2019-06-11 |
University Of Iowa Foundation |
Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
|
WO2016184963A1
(en)
|
2015-05-19 |
2016-11-24 |
Innavirvax |
Treatment of hiv-infected individuals
|
WO2016184962A1
(en)
|
2015-05-19 |
2016-11-24 |
Innavirvax |
Treatment of hiv-infected individuals
|
US20160339030A1
(en)
|
2015-05-19 |
2016-11-24 |
University Of Maryland, Baltimore |
Treatment agents for inhibiting hiv and cancer in hiv infected patients
|
WO2016184973A1
(en)
|
2015-05-19 |
2016-11-24 |
Innavirvax |
Treatment of hiv-infected individuals
|
EP3297660A2
(en)
|
2015-05-20 |
2018-03-28 |
The Broad Institute Inc. |
Shared neoantigens
|
HUE060376T2
(hu)
|
2015-05-21 |
2023-02-28 |
Chemocentryx Inc |
Ccr2 modulátorok
|
CN107708674A
(zh)
|
2015-05-22 |
2018-02-16 |
阿菲欧斯公司 |
联合hiv疗法
|
CN107531722B
(zh)
|
2015-05-26 |
2020-07-17 |
豪夫迈·罗氏有限公司 |
杂环雌激素受体调节剂及其用途
|
CN104892648A
(zh)
|
2015-05-27 |
2015-09-09 |
天津工业大学 |
一种负载抗肿瘤药物的靶向金属有机骨架的制备及用途
|
US20180164317A1
(en)
|
2015-05-28 |
2018-06-14 |
Bayer Pharma Aktiengesellschaft |
Method for stratification of melanoma patients by determination of oxygen consumption, ppargc1a, ppargc1b and mitf levels
|
WO2016196471A1
(en)
|
2015-06-02 |
2016-12-08 |
Cooper Human Systems Llc |
Methods and compositions for treatment of hiv infection
|
CA2988306A1
(en)
|
2015-06-05 |
2016-12-08 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of demyelinating diseases
|
JP6721252B2
(ja)
|
2015-06-05 |
2020-07-08 |
ミラゲン セラピューティクス, インコーポレイテッド |
皮膚T細胞リンパ腫(CTCL)を処置するためのmiR−155阻害剤
|
JP6830909B2
(ja)
|
2015-06-08 |
2021-02-17 |
ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ |
mIDH1阻害剤としてのN−メンチルベンズイミダゾール
|
CA2986441A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
EP3307749A4
(en)
|
2015-06-15 |
2019-06-19 |
Hangzhou Dac Biotech Co., Ltd |
HYDROPHILIC LINKER FOR CONJUGATION
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|
US10766962B2
(en)
|
2015-06-16 |
2020-09-08 |
The Regents Of The University Of California |
FZD7 specific antibodies and vaccines to treat cancer and control stem cell function
|
WO2016205566A1
(en)
|
2015-06-16 |
2016-12-22 |
The Regents Of The University Of California |
Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
|
WO2016202758A1
(en)
|
2015-06-18 |
2016-12-22 |
Bayer Pharma Aktiengesellschaft |
Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
|
WO2016202756A1
(en)
|
2015-06-18 |
2016-12-22 |
Bayer Pharma Aktiengesellschaft |
Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
|
EP3310168A4
(en)
|
2015-06-19 |
2019-03-06 |
Trustees of Boston University |
METHODS AND COMPOSITIONS FOR TREATING CONDITIONS INDUCED BY HERPETIC VIRUS
|
CN107921144B
(zh)
|
2015-06-20 |
2023-11-28 |
杭州多禧生物科技有限公司 |
澳瑞他汀类似物及其与细胞结合分子的共轭偶联物
|
CA2990076A1
(en)
|
2015-06-22 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
|
JP2018528161A
(ja)
|
2015-06-23 |
2018-09-27 |
バイエル ファーマ アクチエンゲゼルシャフト |
Ksp阻害剤との部位特異的均一複合体
|
CN107921146A
(zh)
|
2015-06-23 |
2018-04-17 |
拜耳医药股份有限公司 |
纺锤体驱动蛋白(ksp)抑制剂与抗‑cd123的抗体的抗体药物缀合物(adc)
|
CA2990394A1
(en)
|
2015-06-23 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
|
WO2016210289A1
(en)
|
2015-06-24 |
2016-12-29 |
Duke University |
Chemical modulators of signaling pathways and therapeutic use
|
WO2016210247A1
(en)
|
2015-06-24 |
2016-12-29 |
Duke University |
New methods of use for an anti-diarrhea agent
|
US20180353602A1
(en)
|
2015-06-29 |
2018-12-13 |
Syndax Pharmaceuticals, Inc. |
Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
|
KR20180019229A
(ko)
|
2015-06-29 |
2018-02-23 |
아브락시스 바이오사이언스, 엘엘씨 |
나노입자 mTOR 억제제 조합 요법을 사용하여 고형 종양을 치료하는 방법
|
CN107921050A
(zh)
|
2015-06-29 |
2018-04-17 |
阿布拉科斯生物科学有限公司 |
使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
|
WO2017003995A1
(en)
|
2015-06-29 |
2017-01-05 |
Merck Patent Gmbh |
TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF
|
WO2017003908A1
(en)
|
2015-06-30 |
2017-01-05 |
The Trustees Of Columbia University In The City Of New York |
Talc-bound compositions and uses thereof
|
TW201708210A
(zh)
|
2015-06-30 |
2017-03-01 |
葛蘭素史克智慧財產(第二)有限公司 |
Zeste同源物2增強子之抑制劑
|
CN113698335A
(zh)
|
2015-07-04 |
2021-11-26 |
杭州多禧生物科技有限公司 |
细胞结合分子的特异性偶联
|
ES2877424T3
(es)
|
2015-07-07 |
2021-11-16 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
2-Aril- y 2-arilalquil-bencimidazoles como inhibidores de MIDH1
|
WO2017008046A1
(en)
|
2015-07-08 |
2017-01-12 |
Children's Hospital Medical Center |
Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
|
US10045985B2
(en)
|
2015-07-09 |
2018-08-14 |
Merck Patent Gmbh |
Heteroaryl compounds as BTK inhibitors and uses thereof
|
WO2017005711A1
(de)
|
2015-07-09 |
2017-01-12 |
Bayer Pharma Aktiengesellschaft |
Phosphor- und schwefel-substituierte benzodiazepin-derivate
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
US10292961B2
(en)
|
2015-07-15 |
2019-05-21 |
Hangzhou Dac Biotech Co., Ltd. |
Disulfur bridge linkers for conjugation of a cell-binding molecule
|
CN108026052B
(zh)
|
2015-07-16 |
2021-10-08 |
德国癌症研究公共权益基金会 |
作为mIDH1抑制剂的5-羟烷基苯并咪唑类
|
GB201512869D0
(en)
|
2015-07-21 |
2015-09-02 |
Almac Diagnostics Ltd |
Gene signature for minute therapies
|
EP3121166A1
(en)
|
2015-07-21 |
2017-01-25 |
Bayer Pharma Aktiengesellschaft |
Fused imidazoles as midh1 inhibitors
|
WO2017019767A1
(en)
|
2015-07-27 |
2017-02-02 |
Myosotis, Llc |
Inhibition of CXCL12 in Cancer Immunotherapy
|
KR20180072665A
(ko)
|
2015-07-28 |
2018-06-29 |
베타 캐트 파마슈티칼스, 인코포레이티드 |
안트라센-9,10-디온 디옥심 화합물 전구약물 및 이의 용도
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
WO2017018476A1
(ja)
|
2015-07-29 |
2017-02-02 |
塩野義製薬株式会社 |
キナゾリン誘導体の塩またはその結晶およびそれらの製造方法
|
JP6878405B2
(ja)
|
2015-07-29 |
2021-05-26 |
ノバルティス アーゲー |
Pd−1に対する抗体分子を含む組み合わせ治療
|
EP3124609A1
(en)
|
2015-07-29 |
2017-02-01 |
IFOM Fondazione Istituto Firc di Oncologia Molecolare |
Therapeutics oligonucleotides
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
MX2018001074A
(es)
|
2015-07-29 |
2018-11-12 |
Onkimmune Ltd |
Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad.
|
CA2991868A1
(en)
|
2015-07-31 |
2017-02-09 |
Vascular Biogenics Ltd. |
Motile sperm domain containing protein 2 and cancer
|
TWI665178B
(zh)
|
2015-08-03 |
2019-07-11 |
夸德里加生物科學公司 |
作為化療劑的β-取代的β-氨基酸和類似物及其應用
|
WO2017021348A1
(en)
|
2015-08-05 |
2017-02-09 |
Bayer Pharma Aktiengesellschaft |
1h-pyrrol-3-amines
|
WO2017023994A1
(en)
|
2015-08-06 |
2017-02-09 |
Yale University |
Small molecule based antibody-recruiting compounds for cancer treatment
|
EP3332257A1
(en)
|
2015-08-07 |
2018-06-13 |
Thomas Helledays Stiftelse För Medicinsk Forskning |
Method for diagnosisng cancer or cancer-associated thrombosis by measuring levels of h3cit in plasma
|
WO2017025493A1
(en)
|
2015-08-12 |
2017-02-16 |
Bayer Pharma Aktiengesellschaft |
Quinoline ezh2 inhibitors
|
US10363226B2
(en)
|
2015-08-12 |
2019-07-30 |
North Carolina State University |
Platelet membrane-coated drug delivery system
|
EP3133165A1
(en)
|
2015-08-17 |
2017-02-22 |
F. Hoffmann-La Roche AG |
Methods for personalizing patient cancer therapy with anti angiogenic compounds
|
US10633399B2
(en)
|
2015-08-17 |
2020-04-28 |
Channel Therapeutics, Inc. |
Functionalized aminobenzoboroxoles
|
GB201514756D0
(en)
|
2015-08-19 |
2015-09-30 |
Karus Therapeutics Ltd |
Compound and method of use
|
WO2017034234A1
(ko)
|
2015-08-21 |
2017-03-02 |
서울대학교 산학협력단 |
Hdac 억제제 내성을 갖는 암 치료용 복합제제
|
US20170056352A1
(en)
|
2015-08-25 |
2017-03-02 |
Rgenix, Inc. |
PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
|
US20180250320A1
(en)
|
2015-08-26 |
2018-09-06 |
The Johns Hopkins University |
Compositions and methods for treating solid tumors
|
MA42684A
(fr)
|
2015-08-26 |
2018-07-04 |
Gilead Sciences Inc |
Modulateurs deutérés du récepteur toll
|
JP6917375B2
(ja)
|
2015-09-01 |
2021-08-11 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
血液がんの治療または予防に有用な化合物および方法
|
RU2018111407A
(ru)
|
2015-09-02 |
2019-10-03 |
Синдакс Фармасьютикалз, Инк. |
Отбор пациентов для комбинированной терапии
|
WO2017040953A1
(en)
|
2015-09-02 |
2017-03-09 |
Wayne State University |
Compositions and methods relating to rad6 inhibition
|
US20170114098A1
(en)
|
2015-09-03 |
2017-04-27 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
DE102015012050A1
(de)
|
2015-09-15 |
2017-03-16 |
Merck Patent Gmbh |
Verbindungen als ASIC-Inhibitoren und deren Verwendungen
|
WO2017046142A1
(en)
|
2015-09-15 |
2017-03-23 |
Stichting Katholieke Universiteit |
IMPROVED METHOD FOR EX VIVO EXPANSION CD34+HSPCs INTO NK CELLS USING AN ARYL HYDROCARBON RECEPTOR ANTAGONIST
|
DE102015012049A1
(de)
|
2015-09-15 |
2017-03-16 |
Merck Patent Gmbh |
Verbindungen als ASIC-Inhibitoren und deren Verwendungen
|
MX2018002986A
(es)
|
2015-09-18 |
2018-05-02 |
Merck Patent Gmbh |
Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
|
BR112018003812B1
(pt)
|
2015-09-18 |
2024-04-30 |
Merck Patent Gmbh |
Compostos de heteroarila como inibidores de irak, seu uso, composição farmacêutica, e kit
|
JP2018535245A
(ja)
|
2015-09-20 |
2018-11-29 |
エアー クロス、インコーポレイテッド |
化合物の活性化のためのオゾン分解、およびオゾンの分解
|
MX2018003291A
(es)
|
2015-09-21 |
2019-02-07 |
Ifom Fondazione St Firc Di Oncologia Molecolare |
Nuevas estrategias terapeuticas contra el cáncer de sangre.
|
PE20181093A1
(es)
|
2015-09-21 |
2018-07-09 |
Plexxikon Inc |
Compuestos heterociclicos y usos de los mismos
|
WO2017053823A1
(en)
|
2015-09-25 |
2017-03-30 |
Pharmacyclics Llc |
Treatment using hdac inhibitors and immunotherapy
|
NZ742001A
(en)
|
2015-09-29 |
2019-06-28 |
Kangpu Biopharmaceuticals Ltd |
Pharmaceutical composition and application thereof comprising a benzoheterocyclic compound
|
JP2018529714A
(ja)
|
2015-09-30 |
2018-10-11 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hivの処置のための化合物および組合せ物
|
WO2017055313A1
(en)
|
2015-10-01 |
2017-04-06 |
Bayer Pharma Aktiengesellschaft |
Amido-substituted azole compounds
|
WO2017055316A1
(en)
|
2015-10-01 |
2017-04-06 |
Bayer Pharma Aktiengesellschaft |
Amido-substituted azole compounds
|
JP2018530550A
(ja)
|
2015-10-01 |
2018-10-18 |
ギリアド サイエンシズ, インコーポレイテッド |
癌を治療するためのbtk阻害剤とチェックポイント阻害剤との組合せ
|
US10544156B2
(en)
|
2015-10-02 |
2020-01-28 |
Pierre Fabre Medicament |
Hemi-synthetic trilobine analogs for use as a drug
|
TW201726130A
(zh)
|
2015-10-02 |
2017-08-01 |
基利科學股份有限公司 |
用於治療癌症之組合療法
|
PL3359542T3
(pl)
|
2015-10-09 |
2021-09-20 |
Boehringer Ingelheim International Gmbh |
Związki i pochodne spiro[3h-indolo-3,2’-pirolidyno]-2(1h)-onowe jako inhibitory mdm2-p53
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
WO2017063966A1
(en)
|
2015-10-13 |
2017-04-20 |
Bayer Pharma Aktiengesellschaft |
Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds
|
CN105288648B
(zh)
|
2015-10-14 |
2018-11-06 |
东南大学 |
一种亲水性药物的磷脂化合物、其药物组合物及应用
|
EP3362075B1
(en)
|
2015-10-15 |
2023-06-07 |
Celularity Inc. |
Natural killer cells and ilc3 cells and uses thereof
|
WO2017063959A1
(de)
|
2015-10-15 |
2017-04-20 |
Bayer Pharma Aktiengesellschaft |
N-sulfoximinophenyl-substituierte benzodiazepin-derivate als bet-proteininhibitoren
|
WO2017070198A1
(en)
|
2015-10-19 |
2017-04-27 |
Dana-Farber Cancer Institute, Inc. |
Polymerase q as a target in hr-deficient cancers
|
KR20180067677A
(ko)
|
2015-10-23 |
2018-06-20 |
다이이찌 산쿄 가부시키가이샤 |
Aml 치료에 사용하기 위한 약학 조성물 및 이를 필요로 하는 피험체에서 aml의 치료 방법
|
US20170115275A1
(en)
|
2015-10-23 |
2017-04-27 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development
|
CN113521069A
(zh)
|
2015-10-23 |
2021-10-22 |
第一三共株式会社 |
用于治疗癌症的mdm2抑制剂的给药方案
|
US11492670B2
(en)
|
2015-10-27 |
2022-11-08 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017079112A1
(en)
|
2015-11-03 |
2017-05-11 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
CN108884159A
(zh)
|
2015-11-07 |
2018-11-23 |
茂体外尔公司 |
用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
|
CN105457038A
(zh)
|
2015-11-09 |
2016-04-06 |
东南大学 |
一种速释型药物磷脂化合物及其药物组合物
|
BR112018009361A8
(pt)
|
2015-11-10 |
2019-02-26 |
Univ Yale |
composições e métodos para o tratamento de doenças autoimunes e de câncer
|
LT3373959T
(lt)
|
2015-11-12 |
2022-07-25 |
Hookipa Biotech Gmbh |
Arenavirusų dalelės, kaip vėžio vakcinos
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
TWI734715B
(zh)
|
2015-11-19 |
2021-08-01 |
美商卡默森屈有限公司 |
趨化因子受體調節劑
|
TWI724056B
(zh)
|
2015-11-19 |
2021-04-11 |
美商卡默森屈有限公司 |
Cxcr2抑制劑
|
TWI730013B
(zh)
|
2015-11-20 |
2021-06-11 |
生華生物科技股份有限公司 |
用於治療癌症的四環喹諾酮類似物組合療法
|
WO2017091777A1
(en)
|
2015-11-24 |
2017-06-01 |
Vijay Krishnan |
Novel healthcare delivery, treatment, and payment model for specialty drugs
|
JP2019501151A
(ja)
|
2015-12-01 |
2019-01-17 |
ゲンマブ ビー.ブイ. |
抗デスレセプター抗体およびその使用方法
|
EP3384050A4
(en)
|
2015-12-03 |
2019-07-31 |
Alfred Health |
MONITORING THE TREATMENT OR PROGRESSION OF MYELOMA
|
WO2017093272A1
(en)
|
2015-12-03 |
2017-06-08 |
Bayer Pharma Aktiengesellschaft |
Furane derivatives as inhibitors of atad2
|
US10722529B2
(en)
|
2015-12-03 |
2020-07-28 |
Temple University—Of the Commonwealth System of Higher Education |
Modulation of NAD+ metabolic pathways for treatment of disease
|
RS60823B1
(sr)
|
2015-12-04 |
2020-10-30 |
Boehringer Ingelheim Int |
Biparatopski polipeptidi koji antagonizuju wnt signalizaciju u tumorskim ćelijama
|
CN106821965A
(zh)
|
2015-12-04 |
2017-06-13 |
中国科学院大连化学物理研究所 |
一种维甲酸多药共递送纳米粒溶液及其制备和应用
|
JP6867652B2
(ja)
|
2015-12-09 |
2021-05-12 |
メディツィニシェ ウニベルジテート ウィーン |
癌療法のためのモノマレイミド官能化白金化合物
|
US10969392B2
(en)
|
2015-12-10 |
2021-04-06 |
Vanderbilt University |
Methods and systems for predicting response to immunotherapies for treatment of cancer
|
TWI814056B
(zh)
|
2015-12-15 |
2023-09-01 |
美商基利科學股份有限公司 |
人類免疫不全病毒中和抗體
|
MA43576A
(fr)
|
2015-12-16 |
2018-11-14 |
Merck Sharp & Dohme |
Anticorps anti-lag3 et fragments de fixation à l'antigène
|
CA3008393A1
(en)
|
2015-12-16 |
2017-06-22 |
Bayer Pharma Aktiengesellschaft |
Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones
|
DK3889145T3
(da)
|
2015-12-17 |
2024-03-18 |
Merck Patent Gmbh |
8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
AU2016370916A1
(en)
|
2015-12-17 |
2018-06-07 |
Gilead Sciences, Inc. |
Tank-binding kinase inhibitor compounds
|
WO2017102091A1
(en)
|
2015-12-18 |
2017-06-22 |
Bayer Pharma Aktiengesellschaft |
Heteroarylbenzimidazole compounds
|
EP3389711A1
(en)
|
2015-12-18 |
2018-10-24 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
US20200268720A1
(en)
|
2015-12-22 |
2020-08-27 |
Glaxosmithkline Llc |
Methods of use of a class iia hdac inhibitor
|
EP3405478A4
(en)
|
2015-12-23 |
2019-10-30 |
Moonshot Pharma LLC |
METHOD FOR INDUCING AN IMMUNE RESPONSE BY INHIBITING NONSENSE-MEDIATED CRASH
|
MX2018008008A
(es)
|
2015-12-28 |
2018-11-09 |
Syndax Pharmaceuticals Inc |
Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico.
|
JP7019578B2
(ja)
|
2015-12-30 |
2022-02-15 |
セルジーン コーポレイション |
Tリンパ球の産生方法及びそれにより産生されるtリンパ球
|
US10189797B2
(en)
|
2015-12-30 |
2019-01-29 |
Duke University |
Chemical modulators of immune checkpoints and therapeutic use
|
EP3400009A2
(en)
|
2016-01-05 |
2018-11-14 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Combination of histone deacetylase inhibitor and immunotherapy
|
EP3778881A1
(en)
|
2016-01-08 |
2021-02-17 |
Replimune Limited |
Modified oncolytic virus
|
EP3402477A4
(en)
|
2016-01-11 |
2019-08-21 |
The Rockefeller University |
METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH SUPPRESSIVE CELLS DERIVED FROM MYELOID CELLS
|
JP6873145B2
(ja)
|
2016-01-14 |
2021-05-19 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
5−置換2−(モルホリン−4−イル)−1,7−ナフチリジン
|
JP2019506897A
(ja)
|
2016-01-19 |
2019-03-14 |
セルジーン コーポレイション |
ヒトのセレブロンを発現するトランスジェニックマウス
|
KR20180101521A
(ko)
|
2016-01-19 |
2018-09-12 |
얀센 파마슈티카 엔.브이. |
Btk 저해제를 포함하는 제형/조성물
|
WO2017132541A1
(en)
|
2016-01-27 |
2017-08-03 |
University Of Maryland, Baltimore |
A method for monitoring cancer and for regulation of semaphorin 4d to improve cancer immunotherapy regimens
|
CN108883179A
(zh)
|
2016-01-28 |
2018-11-23 |
印第安纳大学研究与技术公司 |
组蛋白脱乙酰酶抑制剂用于增强免疫治疗的用途
|
ES2849559T3
(es)
|
2016-01-29 |
2021-08-19 |
Epigenomics Ag |
Métodos para detectar metilación CpG de ADN derivado de tumor en muestras de sangre
|
GB201601773D0
(en)
|
2016-02-01 |
2016-03-16 |
Renishaw Plc |
Method
|
MX2018009368A
(es)
|
2016-02-01 |
2018-09-05 |
Bayer Pharma AG |
Biomarcadores para copanlisib.
|
CN109072307A
(zh)
|
2016-02-01 |
2018-12-21 |
拜耳制药股份公司 |
Copanlisib生物标志物
|
US11078277B2
(en)
|
2016-02-02 |
2021-08-03 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer
|
WO2017136342A1
(en)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
|
CA3209672A1
(en)
|
2016-02-04 |
2016-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
|
CA3013402C
(en)
|
2016-02-05 |
2024-05-28 |
Bayer Pharma Aktiengesellschaft |
Compounds, compositions and methods for cancer patient stratification and cancer treatment
|
RU2753543C1
(ru)
|
2016-02-08 |
2021-08-17 |
Бейондспринг Фармасьютикалс, Инк. |
Композиции, содержащие тукаресол или его аналоги
|
CA3011372A1
(en)
|
2016-02-10 |
2017-08-17 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
WO2017143035A2
(en)
|
2016-02-17 |
2017-08-24 |
The Penn State Research Foundation |
Method and therapeutic use of pign and other genes or genes products that pign interacts with for prognosis and treatment of hematological neoplasias
|
US11311540B2
(en)
|
2016-02-17 |
2022-04-26 |
Acetylon Pharmaceuticals, Inc. |
Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs
|
US20200121699A1
(en)
|
2016-02-22 |
2020-04-23 |
Onxeo |
Combination therapies comprising immuno-oncology agents and belinostat
|
WO2017145162A1
(en)
|
2016-02-23 |
2017-08-31 |
Chaya Brodie |
Generation of cancer stem cells and use thereof
|
US20170247690A1
(en)
|
2016-02-25 |
2017-08-31 |
Agenovir Corporation |
Oncoviral treatment with nuclease and chemotherapeutic
|
JP2019510752A
(ja)
|
2016-03-04 |
2019-04-18 |
ギリアード サイエンシーズ, インコーポレイテッド |
オートタキシン阻害剤の組成物及び合剤
|
WO2017148995A1
(en)
|
2016-03-04 |
2017-09-08 |
Bayer Pharma Aktiengesellschaft |
1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
JP6935415B2
(ja)
|
2016-03-08 |
2021-09-15 |
バイエル ファーマ アクチエンゲゼルシャフト |
2−アミノ−N−[7−メトキシ−2,3−ジヒドロイミダゾ−[1,2−c]キナゾリン−5−イル]ピリミジン−5−カルボキサミド類
|
US20190054057A1
(en)
|
2016-03-08 |
2019-02-21 |
The Board Of Regents For Oklahoma State University Office Of Intellectual Property Management |
Immune boosting dietary compounds for disease control and prevention
|
US10717774B2
(en)
|
2016-03-14 |
2020-07-21 |
Kiromic, Inc. |
Compositions and methods for treating cancers
|
WO2017157418A1
(en)
|
2016-03-15 |
2017-09-21 |
Bayer Pharma Aktiengesellschaft |
Combination of mknk1-inhibitors
|
US20190077856A1
(en)
|
2016-03-15 |
2019-03-14 |
Memorial Sloan Kettering Cancer Center |
Method of treating diseases using kinase modulators
|
US20170268001A1
(en)
|
2016-03-16 |
2017-09-21 |
The University Of Chicago |
Rnas with tumor radio/chemo-sensitizing and immunomodulatory properties and methods of their preparation and application
|
EP3219329A1
(en)
|
2016-03-17 |
2017-09-20 |
Bayer Pharma Aktiengesellschaft |
Combinations of copanlisib
|
WO2017157992A1
(en)
|
2016-03-18 |
2017-09-21 |
Bayer Pharma Aktiengesellschaft |
Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
|
WO2017157991A1
(en)
|
2016-03-18 |
2017-09-21 |
Bayer Pharma Aktiengesellschaft |
1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
|
EP3429513A4
(en)
|
2016-03-18 |
2020-03-18 |
Procept Biorobotics Corporation |
MINIMALLY INVASIVE METHODS AND SYSTEMS FOR HEMOSTASIS OF CLOSED HEMORRHAGIC TISSUE VOLUME
|
US20170273926A1
(en)
|
2016-03-24 |
2017-09-28 |
Orbus Therapeutics, Inc. |
Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
|
CN105949114A
(zh)
|
2016-06-27 |
2016-09-21 |
山东川成医药股份有限公司 |
一种西达本胺的合成方法
|
CN106866571B
(zh)
|
2017-01-20 |
2018-06-29 |
中国药科大学 |
杂环脲类化合物及其药物组合物和应用
|
JP6773915B2
(ja)
|
2017-02-13 |
2020-10-21 |
カング バイオファーマシューティカルズ リミテッド |
前立腺癌を治療する組み合わせ、薬物組成物および治療方法
|
CN106916101B
(zh)
|
2017-02-15 |
2020-05-01 |
聚缘(上海)生物科技有限公司 |
Nampt/hdac双靶点抑制剂及其制备方法
|
CN107011238B
(zh)
|
2017-03-14 |
2020-05-01 |
北京化工大学 |
一类组蛋白去乙酰化酶抑制剂及其制备方法和用途
|